middle.news
How Nyrada’s Xolatryp Is Advancing Neuro and Cardioprotection with Safe Phase I Results
9:10am on Thursday 31st of July, 2025 AEST
•
Biotechnology
Read Story
How Nyrada’s Xolatryp Is Advancing Neuro and Cardioprotection with Safe Phase I Results
9:10am on Thursday 31st of July, 2025 AEST
Key Points
Five Phase I cohorts completed without safety issues; sixth cohort dosed
Phase I protocol amended for higher doses and longer infusion
Preclinical studies show significant neuroprotection in traumatic brain injury
42% cardioprotection and reduced arrhythmia in coronary heart disease model
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE